North Dakota State Investment Board Acquires New Holdings in Boston Scientific Corporation $BSX

North Dakota State Investment Board acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 50,618 shares of the medical equipment provider’s stock, valued at approximately $4,826,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Boston Scientific by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after purchasing an additional 1,436,550 shares during the period. Invesco Ltd. boosted its position in Boston Scientific by 0.7% during the 3rd quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock worth $1,656,131,000 after acquiring an additional 111,826 shares during the last quarter. Northern Trust Corp boosted its position in Boston Scientific by 0.9% during the 3rd quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider’s stock worth $1,406,129,000 after acquiring an additional 128,188 shares during the last quarter. Amundi boosted its position in Boston Scientific by 17.5% during the 3rd quarter. Amundi now owns 11,981,584 shares of the medical equipment provider’s stock worth $1,158,619,000 after acquiring an additional 1,781,830 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Boston Scientific by 4.6% during the 3rd quarter. Legal & General Group Plc now owns 10,457,175 shares of the medical equipment provider’s stock worth $1,020,934,000 after purchasing an additional 463,889 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Down 0.0%

BSX opened at $52.67 on Monday. Boston Scientific Corporation has a 1-year low of $52.52 and a 1-year high of $109.50. The stock’s fifty day simple moving average is $63.40 and its 200 day simple moving average is $81.65. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The stock has a market cap of $78.27 billion, a PE ratio of 22.04, a price-to-earnings-growth ratio of 0.97 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the prior year, the business earned $0.75 EPS. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BSX. Truist Financial dropped their price objective on Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, April 23rd. BTIG Research dropped their price objective on Boston Scientific from $90.00 to $80.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Mizuho dropped their price objective on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $112.00 price objective on shares of Boston Scientific in a research note on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $93.91.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.